Health ❯ Regulatory Affairs

FDA Approvals

Medications Fast Track Designation Drug Formulations Fast Track Status Clinical Trials Drug Designation Drug Approvals Drug Pricing Orphan Drug Designation Priority Review Drug Development Drug Designations Medical Device Regulations Drug Classification Drug Therapies

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

A failed late‑stage readout has forced a program review, plans for major expense reductions, and deep investor reassessment.

Aidoc Raises $150 Million to Scale FDA-Cleared Imaging AI Platform

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug